18 June 2013
Keywords: gilead, hepsera, performs, well, long-term, hep, trial
Article | 01 May 2006
USA-based biopharmaceutical company Gilead Sciences says that the results of a long-term study of its oral antiviral drug Hepsera
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 May 2006
17 June 2013
© 2013 thepharmaletter.com